4-(氨基甲基)-2-溴苯胺 | 42580-43-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(氨基甲基)-2-溴苯胺
• 英文名称: 3-Brom-4-amino-benzylamin
• 英文别名: 2-Bromo-4-aminomethylaniline；4-(Aminomethyl)-2-bromoaniline
• CAS: 42580-43-8
• 化学式: C₇H₉BrN₂
• 分子量: 201.066
• InChiKey: XZROQRMSJUCXKB-UHFFFAOYSA-N

物化性质

• 沸点：
  309.2±27.0 °C(Predicted)
• 密度：
  1.572±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  52
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(氨基甲基)-2-溴苯胺 在 吡啶 、 盐酸 、 4-二甲氨基吡啶 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 4.0h， 生成 N-[4-(aminomethyl)-2-bromophenyl]methanesulfonamide;hydrochloride
  参考文献：
  名称：

  Novel Potent Antagonists of Transient Receptor Potential Channel, Vanilloid Subfamily Member 1:  Structure−Activity Relationship of 1,3-Diarylalkyl Thioureas Possessing New Vanilloid Equivalents

  摘要：

  Recently, 1,3-diarylalkyl thioureas have merged as one of the promising nonvanilloid TRPV1 antagonists possessing excellent therapeutic potential in pain regulation. In this paper, the full structure-activity relationship for TRPV1 antagonism of a novel series of 1,3-diarylalky thioureas is reported. Exploration of the structure- activity relationship, by systemically modulating three essential pharmacophoric regions, led to six examples of 1,3-dibenzyl thioureas, which exhibit Ca2+ uptake inhibition in rat DRG neuron with IC50 between 10 and 100 nM.

  DOI：

  10.1021/jm0502790
• 作为产物：
  描述：

  4-氨基-3-溴苯腈 在 硼烷四氢呋喃络合物 、 盐酸 作用下， 以 四氢呋喃 为溶剂， 反应 16.0h， 生成 4-(氨基甲基)-2-溴苯胺
  参考文献：
  名称：

  Novel Potent Antagonists of Transient Receptor Potential Channel, Vanilloid Subfamily Member 1:  Structure−Activity Relationship of 1,3-Diarylalkyl Thioureas Possessing New Vanilloid Equivalents

  摘要：

  Recently, 1,3-diarylalkyl thioureas have merged as one of the promising nonvanilloid TRPV1 antagonists possessing excellent therapeutic potential in pain regulation. In this paper, the full structure-activity relationship for TRPV1 antagonism of a novel series of 1,3-diarylalky thioureas is reported. Exploration of the structure- activity relationship, by systemically modulating three essential pharmacophoric regions, led to six examples of 1,3-dibenzyl thioureas, which exhibit Ca2+ uptake inhibition in rat DRG neuron with IC50 between 10 and 100 nM.

  DOI：

  10.1021/jm0502790

文献信息

• Dual Pharmacophores - PDE4-Muscarinic Antagonistics
  申请人：Callahan James Francis

  公开号：US20090203677A1

  公开（公告）日：2009-08-13

  The present invention relates to novel compounds of Formula (I) and their use in the treatment of respiratory diseases, including anti-inflammatory and allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.

  本发明涉及式(I)的新化合物及其在治疗呼吸道疾病中的应用，包括抗炎和过敏疾病，如慢性阻塞性肺疾病（COPD）、哮喘、鼻炎（如过敏性鼻炎）、特应性皮炎或银屑病。
• US4153598A
  申请人：——

  公开号：US4153598A

  公开（公告）日：1979-05-08
• US4217272A
  申请人：——

  公开号：US4217272A

  公开（公告）日：1980-08-12
• US8067408B2
  申请人：——

  公开号：US8067408B2

  公开（公告）日：2011-11-29
• [EN] DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS<br/>[FR] PHARMACOPHORES DUALS, ANTAGONISTES DES RÉCEPTEURS MUSCARINIQUES ET INHIBITEURS DE L'ACTIVITÉ PDE4
  申请人：GLAXO GROUP LTD

  公开号：WO2009100168A1

  公开（公告）日：2009-08-13

  The present invention is directed to novel compounds of Formula (I), pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of/ and or prophylaxis of respiratory diseases, including antiinflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.